Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415658 | 1.00 | PNP (0.66) | PNPMTAP | |
| SCHEMBL1415816 | 1.00 | PNP (0.66) | PNPMTAP | |
| SCHEMBL1415718 | 1.00 | PNP (0.66) | PNPMTAP | |
| SCHEMBL1415359 | 1.00 | PNP (0.66) | PNPMTAP | |
| SCHEMBL1945739 | 0.90 | PNP (0.69) | PNPMTAP | |
| SCHEMBL1948382 | 0.90 | PNP (0.69) | PNPMTAP | |
| SCHEMBL1946527 | 0.90 | PNP (0.69) | PNPMTAP | |
| SCHEMBL1945048 | 0.90 | PNP (0.69) | PNPMTAP | |
| SCHEMBL1947156 | 0.90 | PNP (0.69) | PNPMTAP | |
| SCHEMBL20578735 | 0.84 | PNP (0.66) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | MTAP, TYMP, TPMT | PNP 5/4885MTAP 1/4885 |
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | MTAP, TYMP, TPMT | PNP 5/4885MTAP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.